Mini-Focus Issue: Risk Factors and Outcomes in Chronic Heart FailureClinical ResearchPerformance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry
Graphical abstract
Key Words
Abbreviations and Acronyms
Cited by (0)
Since the start of the EORP (EURObservational Research Programme), the following companies have supported the programme: Abbott Vascular Int. (2011–2014), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2017), Bayer AG (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol-Myers Squibb and Pfizer Alliance (2011–2019), Daiichi Sankyo Europe GmbH (2011–2020), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD–Merck & Co. (2011–2014), Novartis Pharma AG (2014–2017), ResMed (2014–2016), Sanofi (2009–2011), and Servier (2009–2018).
Dr. Chioncel has been on the steering committee for Novartis; and has received research grants from Servier, Vifor, and Novartis. Dr. Crespo-Leiro has received research funds and speaker fees and been on the advisory boards for Novartis, Amgen, Pfizer, and Abbott. Dr. Tavazzi has received personal fees from Servier and CVIE Therapeutics. Dr. Maggioni is a member of the study committees for Novartis and Bayer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.